JP2019508181A5 - - Google Patents

Download PDF

Info

Publication number
JP2019508181A5
JP2019508181A5 JP2018548884A JP2018548884A JP2019508181A5 JP 2019508181 A5 JP2019508181 A5 JP 2019508181A5 JP 2018548884 A JP2018548884 A JP 2018548884A JP 2018548884 A JP2018548884 A JP 2018548884A JP 2019508181 A5 JP2019508181 A5 JP 2019508181A5
Authority
JP
Japan
Prior art keywords
solution
self
cerebrospinal fluid
leakage
assembling peptide
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2018548884A
Other languages
English (en)
Japanese (ja)
Other versions
JP2019508181A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/IB2017/000387 external-priority patent/WO2017158435A1/en
Publication of JP2019508181A publication Critical patent/JP2019508181A/ja
Publication of JP2019508181A5 publication Critical patent/JP2019508181A5/ja
Pending legal-status Critical Current

Links

JP2018548884A 2016-03-18 2017-03-17 脳脊髄液の漏出の閉鎖 Pending JP2019508181A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201662310122P 2016-03-18 2016-03-18
US62/310,122 2016-03-18
PCT/IB2017/000387 WO2017158435A1 (en) 2016-03-18 2017-03-17 Cerebrospinal fluid leakage occlusion

Publications (2)

Publication Number Publication Date
JP2019508181A JP2019508181A (ja) 2019-03-28
JP2019508181A5 true JP2019508181A5 (cg-RX-API-DMAC7.html) 2020-04-23

Family

ID=58645333

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2018548884A Pending JP2019508181A (ja) 2016-03-18 2017-03-17 脳脊髄液の漏出の閉鎖

Country Status (9)

Country Link
US (1) US20210023257A1 (cg-RX-API-DMAC7.html)
EP (1) EP3429645A1 (cg-RX-API-DMAC7.html)
JP (1) JP2019508181A (cg-RX-API-DMAC7.html)
CN (1) CN109195640A (cg-RX-API-DMAC7.html)
AU (1) AU2017232550A1 (cg-RX-API-DMAC7.html)
BR (1) BR112018068939A2 (cg-RX-API-DMAC7.html)
CL (1) CL2018002643A1 (cg-RX-API-DMAC7.html)
MX (1) MX2018011201A (cg-RX-API-DMAC7.html)
WO (1) WO2017158435A1 (cg-RX-API-DMAC7.html)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BR112018068941A2 (pt) 2016-03-18 2019-04-16 3-D Matrix, Ltd. prevenção de adesão de tecidos biológicos
CN115397454A (zh) 2020-03-31 2022-11-25 立美基股份有限公司 通过辐照对自组装肽进行灭菌

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK1879606T3 (da) * 2005-04-25 2013-09-23 Massachusetts Inst Technology Selvorganiserende peptider til fremme af hæmostase
US9162005B2 (en) * 2005-04-25 2015-10-20 Arch Biosurgery, Inc. Compositions for prevention of adhesions and other barrier applications
US7854923B2 (en) * 2006-04-18 2010-12-21 Endomedix, Inc. Biopolymer system for tissue sealing
ES2673947T3 (es) * 2006-04-25 2018-06-26 Massachusetts Institute Of Technology Composiciones y métodos para afectar al movimiento de contaminantes, líquidos corporales u otras entidades y/o afectar a otras condiciones fisiológicas
RU2011118341A (ru) * 2008-10-06 2012-11-20 3-Д Матрикс, Лтд. (Jp) Агент для окклюзии тканей
CN103800941B (zh) * 2012-11-09 2015-04-22 北京银河巴马生物技术股份有限公司 一种i型胶原材料、脑膜或脊膜生物膜片及其制备方法和应用
US20160287744A1 (en) * 2012-11-14 2016-10-06 3-D Matrix Ltd. Vascular embolic system
HK1220145A1 (zh) * 2013-03-14 2017-04-28 3-D Matrix, Ltd 胆漏治疗

Similar Documents

Publication Publication Date Title
Vigani et al. Recent advances in the development of in situ gelling drug delivery systems for non-parenteral administration routes
JP2019508175A5 (cg-RX-API-DMAC7.html)
BRPI0512397A (pt) composto,produto farmacêutico, métodos para suprimir a metástase de cáncer ou o crescimento do cáncer, para prevenir ou tratar uma doença ou condição, para controlar a função placentária, para melhorar a função gonadal, para induzir ou estimular a ovulação, para promover a secreção do hormÈnio gonadotrópico ou promover a secreção do hormÈnio sexual, para suprimir a secreção do hormÈnio gonadotrópico ou suprimir a secreção do hormÈnio sexual, para infra regular hormÈnio gonadrotópico ou hormÈnio sexual, e a proteìna ot7t175 humana, e para realçar a estabilidade no sangue, uso do composto, e, agente para suprimir a secreção do hormÈnio gonadotrópico ou um agente para suprimir a secreção do hormÈnio sexual
US20210031012A1 (en) Treatment of a disease of the gastrointestinal tract with a pde4 inhibitor
EP4527403A3 (en) Dual function proteins and pharmaceutical composition comprising same
US11419954B2 (en) Targeted protein contrast agents, methods of making, and uses thereof
JP2020509048A5 (cg-RX-API-DMAC7.html)
JP2018512454A5 (cg-RX-API-DMAC7.html)
AU2017339970A1 (en) Compounds and methods for activating Tie2 signaling
JP2022095666A (ja) 感染症を治療するステープル化細胞内ターゲティング抗微生物ペプチド
JP2016539921A5 (cg-RX-API-DMAC7.html)
US20230041197A1 (en) Treatment of a disease of the gastrointestinal tract with an immunomodulator
BR112019020451A2 (pt) composições e métodos para se direcionar e matar células-tronco positivas de câncer ?lfa-v beta-3 positiva (cscs) e tratamento de cânceres resistentes ao medicamento
JP2019508181A5 (cg-RX-API-DMAC7.html)
CA2514584A1 (en) Peptide inhibitors of toxins derived from ll-37
JP2018500546A5 (cg-RX-API-DMAC7.html)
Sun et al. Emerging nanotherapeutic strategies targeting gut-X axis against diseases
WO2024006771A3 (en) Collagen peptide-based medicament compositions and uses thereof
EA202090802A1 (ru) Пептидная композиция для лечения повреждений, связанных с возбуждающей нейротоксичностью
JP2019508184A5 (cg-RX-API-DMAC7.html)
JP2021502337A5 (cg-RX-API-DMAC7.html)
Omar et al. Tumor potential in rat wounds after short-and long-term administration of platelet-rich plasma
JP2018527345A (ja) ポリマーおよびその使用方法
Shunmugaperumal et al. Multifunctional nanosized emulsions for theragnosis of life threatening diseases
WO2019055776A3 (en) Compositions and methods for treatment of diseases involving cxcl1 function